CTOs on the Move

ReAlta Life Sciences

www.realtalifesciences.com

 
ReAlta Life Sciences, Inc. is a biotech company dedicated to harnessing the power of the immune system through its PIC1 technology platform, comprised of a family of over 160 engineered peptides, to address life-threatening medical needs.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

ReAlta Life Sciences raised $14M on 04/21/2020
ReAlta Life Sciences raised $20M on 04/28/2021

Similar Companies

New Horizon Agency Group

New Horizon Agency Group is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Paragon Biosciences

Paragon Biosciences invests in and launches biopharmaceutical companies to develop novel therapies for severe medical conditions which do not yet have adequate treatments. Our mission is to help people live longer, healthier lives. Paragon advances that mission through its contribution of Bioscience Innovation Capital(TM): For rare and complex diseases, Paragon analyzes the viability of potential therapies, invests in new biopharmaceutical companies to further develop promising treatments, catalyzes the progress of its portfolio companies through early-incubation services, and provides clinical and regulatory guidance by a team with a near-perfect track record of first-cycle novel drug approvals.

Tetracore

At Tetracore, we focus on animal health, domestic preparedness, antibody, clinical, and immunology products. View our products online.

Invivyd

Invivyd is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. ​​Invivyd`s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. The company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications.

Genesis Therapeutics

Genesis Therapeutics is an innovative biotechnology company engaging its proprietary molecular AI technology to transform clinical outcomes for patients. The company was founded in 2019 out of Stanford University by Evan Feinberg Ph.D., co-founded by Ben Sklaroff, and backed by Vijay Pande, Ph.D.